ABOUT US We want to challenge and improve today's standardized treatments with the help of our AI technology. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs.

Our purpose

Modern medicine is advancing rapidly, yet too many people still die of cancer, drug-resistant bacteria, and other infectious diseases. The demand for new, efficient drugs has never been higher and will only grow. Every day, our artificial intelligence (AI) technology is bringing us closer to a future where we will be able to treat a wide range of critical diseases in a targeted, patient-specific way. We see an immense market for new, efficient and personalized drugs, as well as a substantial way to improve patients' quality of life. This is why our purpose is saving lives with AI-powered immunotherapies.

How we do it

At Evaxion, our AI-powered immunotherapies are at the heart of our work to revolutionize drug development and ultimately save the lives of patients. We bridge AI technology, bioinformatics, and drug development to bring novel immunotherapies to patients. We have used our AI to generate a broad pipeline of candidate immunotherapies that address two of the most significant unmet medical needs worldwide – cancer and infectious diseases.

Why AI?

The predictive power of our AI platforms comes from our ability to process and interpret vast amounts of data. These data are transformed into advanced algorithms that we believe can accurately predict cellular interactions and identify the right target to stimulate a relevant, potentially lifesaving, response.

See our latest corporate presentation here.

Management Evaxion

Leadership Team Evaxion is comprised of an experienced leadership team and advisors with a proven track record from leading pharmaceutical companies and universities.

Per Norlén

Per Norlén

Chief Executive Officer

Per, MD, PhD, joined Evaxion in 2022. He is a board certified physician and associate professor in clinical pharmacology from Lund University, Sweden. Per has more than 20 years of experience from clinical drug development, within both big pharma and biotech companies, with a focus on immuno-oncology. He has held multiple executive leadership positions during the last 14 years. Most recently as Chief Executive Officer at Targinta AB and, prior to that, Chief Executive Officer and Chief Medical Officer at Alligator Bioscience AB. Further, Dr Norlén has extensive business development experience and has entered into several major agreements with international biotech companies and big pharma.

LinkedIn
Andreas Holm Mattsson

Andreas Holm Mattsson

Founder and CAICO (Chief AI and Culture Officer)

Andreas is an experienced bioinformatician from the Technical University of Denmark. Prior to Evaxion, Andreas spent six years at Novo Nordisk developing in silico platforms.

Since the founding of Evaxion in 2008, Andreas has worked on developing Evaxion's in silico platforms, including PIONEER and EDEN, and numerous other in silico tools enabling vaccine discovery in the area of infectious diseases and immuno-oncology.

LinkedIn
Erik Heegaard

Erik Heegaard

Chief Medical Officer

Erik received his MD from the University of Copenhagen and subsequently earned a PhD, became a board certified medical specialist, and was awarded a Doctorate Dissertation (DMSc). He also holds an Executive Master of Business Strategy from Copenhagen Business School.

He has held numerous research and clinical positions, and was a medical manager at Statens Serum Institute. Over the past 15 years, he has gained profound experience in leadership, project management, clinical development and medical affairs during tenures at Bavarian Nordic, Sandia National Laboratories, Novo Nordisk, Novartis and Seagen.

LinkedIn
Birgitte Rønø

Birgitte Rønø

Chief Scientific Officer

Birgitte Rønø, PhD, joined Evaxion as Senior Director of Immuno-Oncology in 2017 and was appointed Chief Scientific Officer in September 2021.

Dr. Rønø has more than 15 years' experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark.

LinkedIn
Bo Karmark

Bo Karmark

Chief Financial officer

Bo Karmark is an experienced CFO and has been a member of executive management in a number of multinational companies within production, B2B, service industry, R&D, and consulting, with a documented ability to streamline, simplify, and uniform. He has operational experience from a successful IPO, has conducted several financing rounds and refinancings, and has experience within M&A.

LinkedIn
Jesper Nyegaard Nissen

Jesper Nyegaard Nissen

Chief Operational Officer

For over 25 years, Jesper Nyegaard Nissen has worked broadly across the pharma value chain in global operations positions anchored in research, development and finance. He has transformed more than 15 business areas across a variety of focus points, including external innovation and collaborations, digitalization of business processes, development and shaping of organizational capacities, and implementation of performance and process improvement structures.

LinkedIn

Careers

Play an instrumental role in the expansion of Evaxion and explore our open positions. At Evaxion, you will work in a fast-paced environment that cultivates a collaborative and innovative spirit. We support one another’s growth and success and believe our core is built upon diverse abilities.

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.